Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cardiology"
DOI: 10.1002/clc.23055
Abstract: It is uncertain whether omega‐3 fatty acids are beneficial in statin‐treated patients. Epanova is a mix of omega‐3 free fatty acids, not requiring co‐ingestion with food, which can lower triglycerides by up to 31%. STRENGTH… read more here.
Keywords: strength; risk; trial; statin ... See more keywords
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Sign Up to like & getrecommendations! Published in 2020 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2020.154221
Abstract: BACKGROUND Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) particle containing apolipoprotein(a) (apo(a)) covalently linked to apolipoprotein B-100 (apoB). Statin-treated patients with elevated Lp(a) have an increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent trials show… read more here.
Keywords: patients elevated; statin treated; pcsk9 inhibition; treated patients ... See more keywords
Statin Treatment Is Associated with Alterations in the Platelet Lipidome
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis and Haemostasis"
DOI: 10.1055/s-0043-1764353
Abstract: BACKGROUND Platelets are key players in the pathophysiology of coronary artery disease (CAD) and platelet hyperreactivity leads to increased risk of developing adverse cardiovascular events. Further, significant changes in the platelet lipidome occur in patients… read more here.
Keywords: statin treatment; treatment; platelet lipidome; statin treated ... See more keywords
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of internal medicine"
DOI: 10.1111/joim.13457
Abstract: BACKGROUND Inhibition of proprotein convertase subtilisin/kexin type 9 with alirocumab decreases plasma lipoprotein(a) [Lp(a)] levels. The kinetic mechanism for lowering Lp(a) by alirocumab may differ according to pre-treatment apolipoprotein(a) [apo(a)] levels. METHODS AND RESULTS The… read more here.
Keywords: patients high; statin treated; treated patients; concentration ... See more keywords
Diagnosis of osteoporosis in statin-treated patients is dose-dependent
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-215714
Abstract: Objective Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Consequently, this study was set out to investigate the relationship of different… read more here.
Keywords: statin; dose dependent; statin treated; diagnosis osteoporosis ... See more keywords
Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients
Sign Up to like & getrecommendations! Published in 2019 at "Vascular Health and Risk Management"
DOI: 10.2147/vhrm.s221289
Abstract: Purpose Real-world data may provide insight into relationships between high triglycerides (TG), a modifiable cardiovascular (CV) risk factor, and increased heart failure (HF) risk. Patients and methods This retrospective administrative claims analysis included statin-treated patients… read more here.
Keywords: diagnosis; treated patients; risk; statin treated ... See more keywords
Circulating PCSK9 in Statin-Treated Patients with Type 2 Diabetes Mellitus (T2DM)
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2217-pub
Abstract: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a natural circulating inhibitor of the LDL receptor. There is evidence that PCSK9 is a risk factor for coronary artery disease. In this study we aimed to determine… read more here.
Keywords: statin; statin treated; pcsk9; circulating pcsk9 ... See more keywords
Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2022.1004264
Abstract: Objectives Statins either barely affect or increase lipoprotein(a) [Lp(a)] levels. This study aimed to explore the factors correlated to the change of Lp(a) levels as well as the relationship between Lp(a) and the recurrent vascular… read more here.
Keywords: change levels; recurrent vascular; statin treated; treated patients ... See more keywords
Efficacy and Safety of Da-Chai-Hu-Tang in Lipid Profiles in High-Risk, Statin-Treated Patients with Residual HyperTG: A 12-Week, Randomized, Active-Control, Open Clinical Study
Sign Up to like & getrecommendations! Published in 2022 at "Life"
DOI: 10.3390/life12030408
Abstract: Da-Chai-Hu-Tang (DCHT) is a herbal extract that has been shown to reduce serum triglyceride (TG) levels in animal experiments as well as small clinical trials. This study aimed to evaluate the efficacy and safety of… read more here.
Keywords: risk statin; patients residual; high risk; statin treated ... See more keywords